Objective: To explore the protective effect of Baoyuan Qiangshen Capsule No. Ⅱ (BYQS) and its mechanism in treating chronic renal failure (CRF). Methods: Sixty CRF patients were divided into 2 groups randomly, the tr...Objective: To explore the protective effect of Baoyuan Qiangshen Capsule No. Ⅱ (BYQS) and its mechanism in treating chronic renal failure (CRF). Methods: Sixty CRF patients were divided into 2 groups randomly, the treated group used BYQS combined with Lotensin and the control group administered with essential amino acid combined with Lotensin. Changes of renal functions and tubular labelled proteins were observed. Results: The markedly effective rate and total effective rate of the treated group were 63.3% and 93.3% respectively, and those of the control group were 30.0% and 56.7% respectively, the effect of the treated group was obviously better than that of the control group ( P <0.01). In the treated group after medication, blood urea nitrogen, serum creatinine and clearance rate of creatinine were improved significantly ( P <0.01), while Tamm Horfau protein increased significantly ( P <0.01). Conclusion: BYQS could alleviate tubular interstitial injury significantly so as to improve the renal function and enhance the effective rate in treating CRF.展开更多
Objective: To evaluate the effect of Baoyuan Qiangshen Tablet No. I (BYQS), a Chinese herbal medicine for reinforcing Kidney, activating circulation and eliminating evil Turbid factors, in prolongating interval of hem...Objective: To evaluate the effect of Baoyuan Qiangshen Tablet No. I (BYQS), a Chinese herbal medicine for reinforcing Kidney, activating circulation and eliminating evil Turbid factors, in prolongating interval of hemodialysis in patients of terminal stage of renal disease (TSRD). Methods : Twenty cases of TSRD were treated with BYQS combined with hemodialysis once every 5 days and the effect was observed and compared with control group treated with routine hemodialysis once every 3 days. Results : The increasing levels of serum creatinine, and blood urea nitrogen of BYQS group at dialysis interval were all lower than those of the control group (P< 0. 01 ). After 3 months' treatment, serum creatinine, blood urea nitrogen of BYQS group were lower than those before treatment, plasma albumin, lipoprotein, urine level of prostaglandin and anemia were all improved to various extent, but the creatinine clearance rate was unchanged. Conclusions : BYQS could prolong the interval and reduce the times of dialysis by way of regulating the lipid metabolic disorder, improving pathological change of kidney and protecting function of residual kidney unit. BYQS combined with hemodialysis is a good way of integrated traditional Chinese and Western medicine in treating TSRD.展开更多
Background:Rheumatoid arthritis(RA)is a worldwide public health problem.Intervention and prevention before the onset of rheumatic diseases is a new direction in current research.Objective:The aim of this study was to ...Background:Rheumatoid arthritis(RA)is a worldwide public health problem.Intervention and prevention before the onset of rheumatic diseases is a new direction in current research.Objective:The aim of this study was to evaluate the potential and feasibility of traditional Chinese medicine(TCM)in the prevention of RA.Methods:This was a single-armed prospective clinical trial.All participants were recruited from a single center in Guangdong,China.Adults who were tested positive for anti-cyclic citrullinated peptide antibody(anti-CCP)and/or rheumatoid factor(RF),had no synovitis and never been treated with disease-modifying anti-rheumatic drugs(DMARDs),were enrolled to take the Huayu-Qiangshen-Tongbi(HQT)decoction orally twice daily,200 mL each time for 24 weeks.Primary outcome was the proportion of patients who met 2010 ACR(American College of Rheumatology)/EULAR(European League Against Rheumatism)classification criteria of RA during observation.Secondary outcomes included levels of anti-CCP,RF,erythrocyte sedimentation rate(ESR),C-reactive protein(CRP),assessment of signs and symptoms,and radiographic progression by magnetic resonance imaging(MRI).Results:19 individuals were enrolled in the study,4 of which withdrew because of the epidemic of COVID-19.During the observation period,3 individuals(20%)developed RA and they had longer morning stiffness(P=0.009)and more obvious synovial enhancement in MRI(P=0.041)at baseline when compared with those who did not develop RA.After 24 weeks of intervention,there were improvements in 28-swollen joint count(SJC28)(P=0.046),Visual Analog Scale(VAS)(P=0.019),Patient’s Global Assessment(PtGA)(P=0.019)and Physician’s Global Assessment(PGA)(P=0.031),but no statistical significance was observed in the levels of anti-CCP,RF,ESR,CRP,morning stiffness,28-tender joint count(TJC28),Health Assessment Questionnaire(HAQ)and magnetic resonance imaging(MRI)analysis(P>0.05).Conclusion:The HQT formula is safe and could improve joint symptoms and signs in these at-risk individuals,but it rem展开更多
文摘Objective: To explore the protective effect of Baoyuan Qiangshen Capsule No. Ⅱ (BYQS) and its mechanism in treating chronic renal failure (CRF). Methods: Sixty CRF patients were divided into 2 groups randomly, the treated group used BYQS combined with Lotensin and the control group administered with essential amino acid combined with Lotensin. Changes of renal functions and tubular labelled proteins were observed. Results: The markedly effective rate and total effective rate of the treated group were 63.3% and 93.3% respectively, and those of the control group were 30.0% and 56.7% respectively, the effect of the treated group was obviously better than that of the control group ( P <0.01). In the treated group after medication, blood urea nitrogen, serum creatinine and clearance rate of creatinine were improved significantly ( P <0.01), while Tamm Horfau protein increased significantly ( P <0.01). Conclusion: BYQS could alleviate tubular interstitial injury significantly so as to improve the renal function and enhance the effective rate in treating CRF.
文摘Objective: To evaluate the effect of Baoyuan Qiangshen Tablet No. I (BYQS), a Chinese herbal medicine for reinforcing Kidney, activating circulation and eliminating evil Turbid factors, in prolongating interval of hemodialysis in patients of terminal stage of renal disease (TSRD). Methods : Twenty cases of TSRD were treated with BYQS combined with hemodialysis once every 5 days and the effect was observed and compared with control group treated with routine hemodialysis once every 3 days. Results : The increasing levels of serum creatinine, and blood urea nitrogen of BYQS group at dialysis interval were all lower than those of the control group (P< 0. 01 ). After 3 months' treatment, serum creatinine, blood urea nitrogen of BYQS group were lower than those before treatment, plasma albumin, lipoprotein, urine level of prostaglandin and anemia were all improved to various extent, but the creatinine clearance rate was unchanged. Conclusions : BYQS could prolong the interval and reduce the times of dialysis by way of regulating the lipid metabolic disorder, improving pathological change of kidney and protecting function of residual kidney unit. BYQS combined with hemodialysis is a good way of integrated traditional Chinese and Western medicine in treating TSRD.
基金This study was supported by the National Natural Science Foun-dation of China(81804041)the special project of State Key Laboratory of Dampness Syndrome of Chinese Medicine(SZ2020ZZ17)+5 种基金the 2020 Guangdong Provincial Science and Technology Innovation Strategy Special Fund(The Guangdong-Hong Kong-Macao Joint Lab)(2020B1212030006)Natural Science Foundation of Guang-dong Province(2021A1515011477,2021A1515011593)grant from Guangzhou Basic Research Program(202102010256)the Key Research Project of Guangzhou University of Chinese Medicine(XK2019021)opening project of Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases(2018)(2018B030322012,MB2020KF03),Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine(ZYYCXTD-C-202204)as well as grants from Guangdong Provincial Hospital of Chinese Medicine(MB2019ZZ07,YN10101906,YN2018ML08,YN2018ZD06)。
文摘Background:Rheumatoid arthritis(RA)is a worldwide public health problem.Intervention and prevention before the onset of rheumatic diseases is a new direction in current research.Objective:The aim of this study was to evaluate the potential and feasibility of traditional Chinese medicine(TCM)in the prevention of RA.Methods:This was a single-armed prospective clinical trial.All participants were recruited from a single center in Guangdong,China.Adults who were tested positive for anti-cyclic citrullinated peptide antibody(anti-CCP)and/or rheumatoid factor(RF),had no synovitis and never been treated with disease-modifying anti-rheumatic drugs(DMARDs),were enrolled to take the Huayu-Qiangshen-Tongbi(HQT)decoction orally twice daily,200 mL each time for 24 weeks.Primary outcome was the proportion of patients who met 2010 ACR(American College of Rheumatology)/EULAR(European League Against Rheumatism)classification criteria of RA during observation.Secondary outcomes included levels of anti-CCP,RF,erythrocyte sedimentation rate(ESR),C-reactive protein(CRP),assessment of signs and symptoms,and radiographic progression by magnetic resonance imaging(MRI).Results:19 individuals were enrolled in the study,4 of which withdrew because of the epidemic of COVID-19.During the observation period,3 individuals(20%)developed RA and they had longer morning stiffness(P=0.009)and more obvious synovial enhancement in MRI(P=0.041)at baseline when compared with those who did not develop RA.After 24 weeks of intervention,there were improvements in 28-swollen joint count(SJC28)(P=0.046),Visual Analog Scale(VAS)(P=0.019),Patient’s Global Assessment(PtGA)(P=0.019)and Physician’s Global Assessment(PGA)(P=0.031),but no statistical significance was observed in the levels of anti-CCP,RF,ESR,CRP,morning stiffness,28-tender joint count(TJC28),Health Assessment Questionnaire(HAQ)and magnetic resonance imaging(MRI)analysis(P>0.05).Conclusion:The HQT formula is safe and could improve joint symptoms and signs in these at-risk individuals,but it rem
